{{medical}}
{{Drugbox
| verifiedrevid = 443508903
| IUPAC_name = (6''R'',7''R'')-7-{[2-(2-amino-1,3-thiazol-4-yl)-2-(carboxy<br>methoxyimino)acetyl]amino}-3-ethenyl-8-oxo-5-thia-<br>1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
| image = Cefixime.svg

<!--Clinical data-->
| tradename = Suprax
| Drugs.com = {{drugs.com|monograph|cefixime}}
| MedlinePlus = a690007
| pregnancy_category = B
| legal_status =  
| routes_of_administration = 口服

<!--Pharmacokinetic data-->
| bioavailability = 40% 到 50%
| protein_bound = 約 60%
| metabolism =  
| elimination_half-life = 平均三到四小時
| excretion = 經[[腎臟|腎臟]]和膀胱

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 79350-37-1
| ATC_prefix = J01
| ATC_suffix = DD08
| ATC_supplemental =  
| PubChem = 5362065
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = APRD00583
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4514923
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 97I1C92E55
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00258
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 472657
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1541

<!--Chemical data-->
| C=16 | H=15 | N=5 | O=7 | S=2 
| molecular_weight = 453.452 g/mol
| smiles = O=C2N1/C(=C(/C=C)CS[C@@H]1[C@@H]2NC(=O)C(=N\OCC(=O)O)/c3nc(sc3)N)C(=O)O
| InChI = 1/C16H15N5O7S2/c1-2-6-4-29-14-10(13(25)21(14)11(6)15(26)27)19-12(24)9(20-28-3-8(22)23)7-5-30-16(17)18-7/h2,5,10,14H,1,3-4H2,(H2,17,18)(H,19,24)(H,22,23)(H,26,27)/b20-9-/t10-,14-/m1/s1
| InChIKey = OKBVVJOGVLARMR-QSWIMTSFBM
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C16H15N5O7S2/c1-2-6-4-29-14-10(13(25)21(14)11(6)15(26)27)19-12(24)9(20-28-3-8(22)23)7-5-30-16(17)18-7/h2,5,10,14H,1,3-4H2,(H2,17,18)(H,19,24)(H,22,23)(H,26,27)/b20-9-/t10-,14-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = OKBVVJOGVLARMR-QSWIMTSFSA-N
}}
'''頭孢克肟'''（{{lang|en|Cefixime}}）是一種口服的第三代[[頭孢菌素|頭孢菌素]][[抗生素|抗生素]]，通常用於治療[[淋病|淋病]]<ref name="McMillan-2007">{{cite journal | author=McMillan A, Young H. |title=The treatment of pharyngeal gonorrhoea with a single oral dose of cefixime | journal=Int J STD AIDS | year=2007 | volume=18 | issue=4 |pages=253–4 | pmid=17509176 | doi=10.1258/095646207780658971}}</ref>、[[扁桃腺炎|扁桃腺炎]]<ref name="Adam-1995">{{cite journal | author=Adam D, Hostalek U, Tröster K. | title=5-day cefixime therapy for bacterial pharyngitis and/or tonsillitis: comparison with 10-day penicillin V therapy | journal=Infection | year=1995 | volume=23 | issue=Suppl 2 |pages=S83–6 | pmid=8537138 | doi=10.1007/BF01742990}}</ref>和[[咽炎|咽炎]]<ref name="Adam-1995" />。

常用劑量為400毫克。

頭孢克肟在美國以「Suprax」的名稱發售，直到2003年，當它的專利失效之後，其專利的原擁有者[[惠氏藥廠|惠氏藥廠]]把它下架。其後，「Suprax」再度由[[盧平藥廠|盧平藥廠]]推出，但改為以口服混懸液形式發售。現時在全世界均有藥廠生產其代用藥，當中最大的生產商位於印度。

== 參考資料 ==
{{reflist}}
{{细胞壁破坏性抗生素}}

[[Category:頭孢菌素|Category:頭孢菌素]]
[[Category:世界卫生组织基本药物|Category:世界卫生组织基本药物]]